These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28985035)

  • 1. Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
    Porta C; Sica A; Riboldi E
    FEBS J; 2018 Feb; 285(4):717-733. PubMed ID: 28985035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
    Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
    Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid suppressor cells in cancer and autoimmunity.
    Sica A; Massarotti M
    J Autoimmun; 2017 Dec; 85():117-125. PubMed ID: 28728794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated myeloid cells in cancer immunotherapy.
    Cheng X; Wang H; Wang Z; Zhu B; Long H
    J Hematol Oncol; 2023 Jul; 16(1):71. PubMed ID: 37415162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy.
    Daveri E; Vergani E; Shahaj E; Bergamaschi L; La Magra S; Dosi M; Castelli C; Rodolfo M; Rivoltini L; Vallacchi V; Huber V
    Front Immunol; 2020; 11():1214. PubMed ID: 32793185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
    Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
    Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
    Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Tumor-Associated Myeloid Cells in Breast Cancer.
    Cha YJ; Koo JS
    Cells; 2020 Jul; 9(8):. PubMed ID: 32726950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental pathways of myeloid-derived suppressor cells in neoplasia.
    Abrams SI
    Cell Immunol; 2021 Feb; 360():104261. PubMed ID: 33373817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad.
    Bleve A; Durante B; Sica A; Consonni FM
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
    Cheung PF; Lutz M; Siveke JT
    Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes.
    Wang H; Liu S; Zhan J; Liang Y; Zeng X
    Int J Cancer; 2024 Jun; 154(12):2031-2042. PubMed ID: 38500385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.
    Hashimoto A; Gao C; Mastio J; Kossenkov A; Abrams SI; Purandare AV; Desilva H; Wee S; Hunt J; Jure-Kunkel M; Gabrilovich DI
    Cancer Res; 2018 Oct; 78(19):5644-5655. PubMed ID: 30139814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.